Clinical trial for Obsessive - Compulsive Disorder
Official title Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder
ClinicalTrials.gov ID: NCT07146438
What this study is testing
- What it's testing
- The study wants to see if adding noninvasive brain stimulation to therapy helps people with OCD and to find clues that predict who will benefit.
- Who it's for
- Adults who have been diagnosed with obsessive‑compulsive disorder.
- What's involved
- Participants will receive brain stimulation while doing either exposure therapy or supportive therapy. They will also wear devices and use a phone app to record data, and will have brain scans before and after treatment.
- Time commitment
- The study lasts several weeks, with multiple visits for therapy, brain stimulation, data collection, and brain scans.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosis of Obsessive-Compulsive Disorder (OCD) as determined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)...
- Live in Southern California and be willing to attend in-person to receive repetitive Transcranial Magnetic Stimulation (rTMS) 5 times per week for 6...
- Have completed a prior course of Exposure and Response Prevention (ERP) therapy (at least ten sessions)
- Currently take or have previously tried Serotonin Reuptake Inhibitor (SRI) medication for OCD
- Willing to maintain psychotropic medication levels throughout the 16 weeks of the study
You likely can't join if
- Primary psychiatric diagnosis other than OCD
- Active substance use disorder
- Active suicidality
- Active psychosis
- History of seizures
- Severe neurological impairment
See the full eligibility criteria
- Diagnosis of Obsessive-Compulsive Disorder (OCD) as determined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria.
- Live in Southern California and be willing to attend in-person to receive repetitive Transcranial Magnetic Stimulation (rTMS) 5 times per week for 6 weeks.
- Have completed a prior course of Exposure and Response Prevention (ERP) therapy (at least ten sessions)
- Currently take or have previously tried Serotonin Reuptake Inhibitor (SRI) medication for OCD
- Willing to maintain psychotropic medication levels throughout the 16 weeks of the study
- Primary psychiatric diagnosis other than OCD
- Active substance use disorder
- Active suicidality
- Active psychosis
- History of seizures
- Severe neurological impairment
- Pregnant or planning to become pregnant
- Received a prior rTMS course
The study team makes the final eligibility decision.
Where it is enrolling
- Los Angeles, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Los Angeles, California, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.